Interim results from the phase II COCOON trial showed a 50% reduction in dermatologic toxicities when proactive skincare was used in frontline EGFR-mutant non-small cell lung cancer patients. The study, led by Bishal Tiwari at Nassau University Medical Center and collaborators, targets an adverse-event burden that can force dose interruptions and affect quality of life. The trial’s design emphasizes prevention rather than reactive management, positioning skincare protocols as an actionable intervention alongside targeted therapy. In EGFR-driven disease, rash and other skin toxicities remain among the most common treatment-limiting events. If validated in full readouts, COCOON’s findings could influence supportive-care standards and trial conduct across biomarker-defined NSCLC populations.